• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tesseract Health Appoints Dr. Michael McConnell as Head of Cardiovascular and Digital Health

    4/28/22 9:00:00 AM ET
    $BFLY
    $HYPR
    $QSI
    Medical Electronics
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BFLY alert in real time by email

    Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company

    Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract's Head of Cardiovascular and Digital Health. This key role completes Tesseract's leadership team and coincides with a series of critical, strategic hires under the helm of CEO Vicky Demas, PhD.

    Dr. McConnell was brought on to leverage Tesseract's technology to guide the expansion of its cardiovascular strategy. In this role, he is poised to lead and champion the design, planning, development and clinical research for cardiovascular health products. Dr. McConnell trained at MIT, Stanford, and Harvard and directed programs in cardiovascular imaging, prevention, and digital health at Stanford Medicine, and then Google, as the senior clinical lead at Google Health/Fitbit.

    "I'm very excited to join Dr. Demas and the Tesseract Health leadership team to advance our mission to democratize point-of-care screening and monitoring of important health conditions," said Dr. McConnell. "My academic and industry career has focused on leveraging technology for early disease detection and prevention, and demonstrated how the eye provides a direct window to see the impact of diabetes, high blood pressure, and risk of heart attack and stroke. I aim to bring my expertise in imaging, prevention, and digital health to develop innovative, new ocular health biomarkers and products to help people around the world live healthier lives."

    Tesseract aims to create a new standard in diagnostics that will bridge imaging technology and laboratory medicine, leveraging technology and AI to detect health conditions through the eyes. To achieve this mission, Tesseract has recruited a diverse team of healthcare, medical device, and technology experts – all with the goal of redesigning the future of healthcare through the deployment of connected, smart devices.

    "I am honored that Dr. McConnell has joined our incredibly talented team to launch an end-to-end solution that enables health screening outside of specialists' offices," states Dr. Demas. "I am confident that our pipeline of non-invasive health products will change the way we address systemic disease moving forward."

    About Tesseract HealthTM

    Tesseract Health is a venture-backed, technology company developing a portable, non-invasive platform to detect health conditions through the eyes, and is part of 4Catalyzer, a medical technology accelerator founded by Dr. Jonathan Rothberg which has launched Butterfly Network (NYSE:BFLY), Quantum-Si (NASDAQ:QSI), Hyperfine and Liminal Sciences (NASDAQ:HYPR), Detect, AI Therapeutics, Tesseract, and Protein Evolution. All of the 4Catalyzer companies are transforming 21st century medicine and improving our planet by solving today's most challenging problems across life science research tools, medical devices, therapeutics and the environment. To learn more, visit: TesseractHealth.com.

    The Tesseract platform is not FDA cleared or available for sale.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005455/en/

    Get the next $BFLY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BFLY
    $HYPR
    $QSI

    CompanyDatePrice TargetRatingAnalyst
    Butterfly Network Inc.
    $BFLY
    7/1/2025$3.00Buy
    Craig Hallum
    Butterfly Network Inc.
    $BFLY
    3/17/2025Outperform
    William Blair
    Quantum-Si Incorporated
    $QSI
    2/7/2025$3.75Buy
    Alliance Global Partners
    Butterfly Network Inc.
    $BFLY
    9/10/2024$3.00Buy
    Lake Street
    Quantum-Si Incorporated
    $QSI
    12/8/2023$3.00Buy
    H.C. Wainwright
    Quantum-Si Incorporated
    $QSI
    9/25/2023$3.50 → $2.00Buy → Hold
    Canaccord Genuity
    Butterfly Network Inc.
    $BFLY
    3/29/2023$2.25Neutral
    UBS
    Butterfly Network Inc.
    $BFLY
    11/29/2022$4.50Outperform
    Oppenheimer
    More analyst ratings

    $BFLY
    $HYPR
    $QSI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Butterfly Network Inc.

      SCHEDULE 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      6/17/25 8:02:11 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Butterfly Network, Inc. (0001804176) (Filer)

      6/17/25 4:15:24 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Quantum-Si Incorporated

      SCHEDULE 13G/A - Quantum-Si Inc (0001816431) (Subject)

      6/6/25 2:58:53 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $BFLY
    $HYPR
    $QSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 29,940,119 shares of common stock (and common stock equivalents) at a purchase price of $1.67 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $50 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about July 8, 2025, subject to the satisfaction of cus

      7/3/25 8:34:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Platinum® Pro Instrument Placed at the Broad Institute to Support Regional Research Initiatives

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the placement of its Platinum® Pro instrument at the Broad Institute. This collaboration aims to support scientific innovation across oncology, therapeutics, and other key areas of biomedical research. This placement expands access to single-molecule protein sequencing within the Broad Institute and the Greater Boston life science ecosystem. Researchers in the region will now have the opportunity to collaborate on advanced applications such as high-resolution protein identification, as well as protein ba

      6/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, announces participation in an expert panel during the upcoming GenomeWeb-hosted webinar, "From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics." When: June 20, 2025, at 8 a.m. PDT/11 a.m. EDT This one-hour webinar will explore critical strategies for improving the accessibility, integration, and standardization of data across proteomics platforms. Attendees will learn how to deposit data into public repositories, apply metadata annotation best practices, normalize cros

      6/19/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $BFLY
    $HYPR
    $QSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hawkins Jeffrey Alan sold $38,257 worth of shares (23,705 units at $1.61), decreasing direct ownership by 0.90% to 2,623,011 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      6/24/25 7:14:41 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Chief Product Officer Vieceli John S. sold $35,382 worth of shares (21,923 units at $1.61), decreasing direct ownership by 3% to 842,586 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      6/24/25 7:11:15 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • GC & Corp. Secretary Lapointe Christian sold $19,280 worth of shares (11,946 units at $1.61), decreasing direct ownership by 1% to 971,534 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      6/24/25 7:06:46 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $BFLY
    $HYPR
    $QSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robbins Larry bought $262,251 worth of shares (244,774 units at $1.07) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      9/4/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Director Robbins Larry bought $1,683,373 worth of shares (1,676,869 units at $1.00) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/30/24 4:18:35 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:25 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $BFLY
    $HYPR
    $QSI
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Butterfly Network Appoints Steve Cashman as Chief Business Officer

      Seasoned Healthcare Leader to Drive Growth Strategy and Amplify Continued Commercial Momentum Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced the appointment of Steve Cashman as Chief Business Officer (CBO), effective today. Cashman joins Butterfly at an exciting juncture, following the Company's successful launch of its third-generation Butterfly iQ3 and historic revenue performance in the first half of 2024. Cashman will join Butterfly's Executive Management Team, overseeing the Company's global sales, marketing, product and corporate strategy. This press release f

      9/3/24 8:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    $HYPR
    $QSI
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Butterfly Network to Report First Quarter 2025 Financial Results on May 2, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report first quarter 2025 financial results on May 2, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on May 2 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Eve

      4/17/25 4:05:00 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    $HYPR
    $QSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Quantum-Si Incorporated

      SC 13D/A - Quantum-Si Inc (0001816431) (Subject)

      9/17/24 4:24:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      9/3/24 7:10:06 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      8/30/24 4:05:41 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    $HYPR
    $QSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Butterfly Network with a new price target

      Craig Hallum initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

      7/1/25 8:24:04 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • William Blair initiated coverage on Butterfly Network

      William Blair initiated coverage of Butterfly Network with a rating of Outperform

      3/17/25 7:23:53 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Alliance Global Partners initiated coverage on Quantum-Si with a new price target

      Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75

      2/7/25 8:29:38 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials